NCT02925312 (T2DMBC) is a NA clinical trial of Diabetes Pathway in Type 2 Diabetes Mellitus, sponsored by Medstar Health Research Institute.

Who is sponsoring NCT02925312?

NCT02925312 is sponsored by Medstar Health Research Institute.

What drugs are being tested in NCT02925312?

Interventions in NCT02925312: Diabetes Pathway.

What condition does NCT02925312 study?

NCT02925312 studies Type 2 Diabetes Mellitus, Hyperglycemia.

Is NCT02925312 still recruiting?

NCT02925312 is currently completed. Last updated 22 September 2020.

Are results published for NCT02925312?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-09-22 · How we verify

NCT02925312: T2DMBC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MedStar Pathway to Diabetes Control Demonstration Project: Type 2 Diabetes Boot Camp

Completed NA Results posted Last updated 22 September 2020

What this trial tests

NA trial testing Diabetes Pathway in Type 2 Diabetes Mellitus in 419 participants. Completed in 31 December 2016.

Timeline

1 November 2014

Primary endpoint
30 June 2016

31 December 2016

Quick facts

Lead sponsor	Medstar Health Research Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	419
Start date	1 November 2014
Primary completion	30 June 2016
Estimated completion	31 December 2016
Sites	1 location across United States

Drugs / interventions tested

Diabetes Pathway

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Hyperglycemia — all drugs for Hyperglycemia →

Sponsor

Medstar Health Research Institute

Who can join

Adults 21 to 75, any sex, with Type 2 Diabetes Mellitus or Hyperglycemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage Change in Hemoglobin A1C From Baseline to 3 Months
Time frame: 3 months
Comparison of the percentage change in A1C from baseline to 3 months between the intervention and the control group

Sponsor's own description

A Diabetes Institute (MDI), in partnership with key stakeholders-including Primary Care Providers- in a northeastern US regional, mixed-payer healthcare system), seeks to implement an evidence-based, technology-enabled, innovative, and integrated diabetes care management pathway (Boot Camp) for adult patients with uncontrolled type 2 diabetes (A1C\>/=9%) which will demonstrate improvement in diabetes clinical and health resources utilization outcomes.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Redesigning ambulatory care management for uncontrolled type 2 diabetes: a prospective cohort study of the impact of a Boot Camp model on outcomes.
Magee MF, Baker KM, Fernandez SJ, Huang CC, et al · · 2019 · cited 15× · PMID 31798894 · DOI 10.1136/bmjdrc-2019-000731
Implications of remote monitoring Technology in Optimizing Traditional Self-Monitoring of blood glucose in adults with T2DM in primary care.
Montero AR, Toro-Tobon D, Gann K, Nassar CM, et al · · 2021 · cited 9× · PMID 34758807 · DOI 10.1186/s12902-021-00884-6

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Medstar Health Research Institute trials

Trials by the same sponsor.

NCT07445932 — Palliative Care Intervention to Improve Health Related Quality of Life for Patients on Long-Term LVAD Support · NA · not yet recruiting
NCT07318545 — Intervention for Chronic Insufficient Sleep in Young Adult Cancer Patients and Survivors · NA · not yet recruiting
NCT07337642 — Comparing Collared and Collarless Femoral Stems in Primary Total Hip Arthroplasty · NA · recruiting
NCT07228377 — Digital Intervention for Symptom Management in Cancer and Opioid Sparing Using Virtual Reality (DISCOVR) Study · NA · recruiting
NCT07223489 — Diagnostic Journey, Patient Experience, and Disparities in the Treatment of Spinal Muscular Atrophy (SMA) in the MedStar · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02925312 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medstar Health Research Institute
Last refreshed: 22 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02925312.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing